|
1
|
Wang K, Shan S, Wang S, Gu X, Zhou X and
Ren T: HMGB1-containing nucleosome mediates chemotherapy-induced
metastasis of human lung cancer. Biochem Biophys Res Commun.
500:758–764. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kumari T and Kumar B: High-mobility group
box 1 protein (HMGB1) gene polymorphisms and cancer susceptibility:
A comprehensive meta-analysis. Clin Chim Acta. 483:170–182.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Osmanov T, Ugrinova I and Pasheva E: The
chaperone like function of the nonhistone protein HMGB1. Biochem
Biophys Res Commun. 432:231–235. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kang R, Xie Y, Zhang Q, Hou W, Jiang Q,
Zhu S, Liu J, Zeng D, Wang H, Bartlett DL, et al: Intracellular
HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res.
27:916–932. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yang L, Wang F, Yang L, Yuan Y, Chen Y,
Zhang G and Fan Z: HMGB1 a-box reverses brain edema and
deterioration of neurological function in a traumatic brain injury
mouse model. Cell Physiol Biochem. 46:2532–2542. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ying S, Xiao X, Chen T and Lou J: PPAR
ligands function as suppressors that target biological actions of
HMGB1. PPAR Res. 2016(2612743)2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wu L and Yang L: The function and
mechanism of HMGB1 in lung cancer and its potential therapeutic
implications. Oncol Lett. 15:6799–6805. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Huang BF, Tzeng HE, Chen PC, Wang CQ, Su
CM, Wang Y, Hu GN, Zhao YM, Wang Q and Tang CH: HMGB1 genetic
polymorphisms are biomarkers for the development and progression of
breast cancer. Int J Med Sci. 15:580–586. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Exner R, Sachet M, Arnold T,
Zinn-Zinnenburg M, Michlmayr A, Dubsky P, Bartsch R, Steger G,
Gnant M, Bergmann M, et al: Prognostic value of HMGB1 in early
breast cancer patients under neoadjuvant chemotherapy. Cancer Med.
5:2350–2358. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Zhang CC, Gdynia G, Ehemann V and Roth W:
The HMGB1 protein sensitizes colon carcinoma cells to cell death
triggered by pro-apoptotic agents. Int J Oncol. 46:667–676.
2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yadav SS, Kumar M, Varshney A and Yadava
PK: KLF4 sensitizes the colon cancer cell HCT-15 to cisplatin by
altering the expression of HMGB1 and hTERT. Life Sci. 220:169–176.
2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Xie B, Cao K, Li J, Chen J, Tang J, Chen
X, Xia K, Zhou X, Cheng Y, Zhou J, et al: Hmgb1 inhibits Klotho
expression and malignant phenotype in melanoma cells by activating
NF-κB. Oncotarget. 7:80765–80782. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Parodi M, Pedrazzi M, Cantoni C, Averna M,
Patrone M, Cavaletto M, Spertino S, Pende D, Balsamo M, Pietra G,
et al: Natural killer (NK)/melanoma cell interaction induces
NK-mediated release of chemotactic high mobility group box-1
(HMGB1) capable of amplifying NK cell recruitment. OncoImmunology.
4(e1052353)2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhou LY, Shi LY and Xiao Y: Changes of
HMGB1 expression on angiogenesis of ovarian cancer and its
mechanism. J Biol Regul Homeost Agents. 30:233–238. 2016.PubMed/NCBI
|
|
15
|
Wu Q, Meng WY, Jie Y and Zhao H: LncRNA
MALAT1 induces colon cancer development by regulating
miR-129-5p/HMGB1 axis. J Cell Physiol. 233:6750–6757.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chen J and Li G: MiR-1284 enhances
sensitivity of cervical cancer cells to cisplatin via
downregulating HMGB1. Biomed Pharmacother. 107:997–1003.
2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wu H and Zhou C: Long non-coding RNA UCA1
promotes lung cancer cell proliferation and migration via
microRNA-193a/HMGB1 axis. Biochem Biophys Res Commun. 496:738–745.
2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Gao H, Gong N, Ma Z, Miao X, Chen J, Cao Y
and Zhang G: LncRNA ZEB2-AS1 promotes pancreatic cancer cell growth
and invasion through regulating the miR-204/HMGB1 axis. Int J Biol
Macromol. 116:545–551. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chen X, Liu X, He B, Pan Y, Sun H, Xu T,
Hu X and Wang S: MiR-216b functions as a tumor suppressor by
targeting HMGB1-mediated JAK2/STAT3 signaling way in colorectal
cancer. Am J Cancer Res. 7:2051–2069. 2017.PubMed/NCBI
|
|
20
|
Wu D, Liu J, Chen J, He H, Ma H and Lv X:
miR-449a suppresses tumor growth, migration, and invasion in
non-small cell lung cancer by targeting a HMGB1-mediated NF-κB
signaling pathway. Oncol Res. 27:227–235. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lv S and Guan M: miRNA-1284, a regulator
of HMGB1, inhibits cell proliferation and migration in
osteosarcoma. Biosci Rep. 38(BSR20171675)2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
He R, Yang L, Lin X, Chen X, Lin X, Wei F,
Liang X, Luo Y, Wu Y, Gan T, et al: MiR-30a-5p suppresses cell
growth and enhances apoptosis of hepatocellular carcinoma cells via
targeting AEG-1. Int J Clin Exp Pathol. 8:15632–15641.
2015.PubMed/NCBI
|
|
24
|
Liu K, Huang J, Ni J, Song D, Ding M, Wang
J, Huang X and Li W: MALAT1 promotes osteosarcoma development by
regulation of HMGB1 via miR-142-3p and miR-129-5p. Cell Cycle.
16:578–587. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Li X, Wang S, Chen Y, Liu G and Yang X:
miR-22 targets the 3'UTR of HMGB1 and inhibits the HMGB1-associated
autophagy in osteosarcoma cells during chemotherapy. Tumour Biol.
35:6021–6028. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Guo S, Bai R, Liu W, Zhao A, Zhao Z, Wang
Y, Wang Y, Zhao W and Wang W: miR-22 inhibits osteosarcoma cell
proliferation and migration by targeting HMGB1 and inhibiting
HMGB1-mediated autophagy. Tumour Biol. 35:7025–7034.
2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Jiang D, Wang H, Li Z, Li Z, Chen X and
Cai H: MiR-142 inhibits the development of cervical cancer by
targeting HMGB1. Oncotarget. 8:4001–4007. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Xia J, Yu X, Song X, Li G, Mao X and Zhang
Y: Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin
resistance in human cervical cancer cells. Mol Med Rep. 15:488–494.
2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lee HJ, Kim A, Song IH, Park IA, Yu JH,
Ahn JH and Gong G: Cytoplasmic expression of high mobility group B1
(HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in
breast cancer. Pathol Int. 66:202–209. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhou RR, Zhao SS, Zou MX, Zhang P, Zhang
BX, Dai XH, Li N, Liu HB, Wang H and Fan XG: HMGB1 cytoplasmic
translocation in patients with acute liver failure. BMC
Gastroenterol. 11(21)2011.PubMed/NCBI View Article : Google Scholar
|
